Table 1:
Characteristics and methodological quality of studies included in meta-analysis
| Reference Number | Country/Ethnicity | Disease Type | Genotyping | -69G>A(rs174538) | 4150G>T(rs4246215) | ||
|---|---|---|---|---|---|---|---|
| case AA/GA/GG | control AA/GA/GG | case TT/GT/GG | control TT/GT/GG | ||||
| 13 | China/ Asian | glioma risk | PCR-RFLP | 35/122/160 | 130/356/316 | 34/120/160 | 130/363/309 |
| 14 | China/ Asian | HCC | PCR-RFLP | 68/290/290 | 134/334/270 | 73/295/280 | 129/335/274 |
| 17 | China/ Asian | EC | PCR-RFLP | 62/249/244 | 128/331/263 | 58/255/225 | 125/336/262 |
| GC | 41/182/189 | 76/209/169 | 42/177/183 | 76/212/166 | |||
| CRC | 28/104/104 | 54/144/109 | 27/102/100 | 52/145/109 | |||
| Breast cancer | 116/437/547 | 246/639/515 | 134/449/517 | 246/651/503 | |||
| 18 | China/ Asian | Lung cancer | PCR-RFLP TaqMan | 253/796/791 | 354/880/724 | 271/815/754 | 358/883/717 |
| 19 | Poland/Caucasian | KC, FECD | PCR-RFLP | 29/262/213 | 17/178/127 | 53/239/212 | 16/157/149 |